Keytruda (pembrolizumab) [package insert]. FDA.

Regulatory approval published by the Food and Drug Administration. Deprecated

Citation

Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s121s122lbl.pdf. Revised October 2021. Accessed October 6, 2026.

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test. 8

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Cisplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Cisplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Carboplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Carboplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab